Informations:
Erreur:
ID
33681
Description
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM); ODM derived from: https://clinicaltrials.gov/show/NCT00908921
Lien
https://clinicaltrials.gov/show/NCT00908921
Mots-clés
Versions (1)
- 19/12/2018 19/12/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
19 décembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Diabetes Mellitus, Type 2 NCT00908921
Eligibility Diabetes Mellitus, Type 2 NCT00908921
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT00908921
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Non-Insulin-Dependent Diabetes Mellitus Newly Diagnosed | Diet therapy Inadequate | Exercise Inadequate | Non-Insulin-Dependent Diabetes Mellitus Disease length | Antidiabetics Oral Absent | Insulin Absent
Item
newly diagnosed t2dm and inadequately controlled with diet and exercise or t2dm diagnosed <6 months and who had not taken oral antidiabetic medication or insulin for >3months.
boolean
C0011860 (UMLS CUI [1,1])
C1518321 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
C0015259 (UMLS CUI [3,1])
C0205412 (UMLS CUI [3,2])
C0011860 (UMLS CUI [4,1])
C0872146 (UMLS CUI [4,2])
C0935929 (UMLS CUI [5,1])
C1527415 (UMLS CUI [5,2])
C0332197 (UMLS CUI [5,3])
C0021641 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
C1518321 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
C0015259 (UMLS CUI [3,1])
C0205412 (UMLS CUI [3,2])
C0011860 (UMLS CUI [4,1])
C0872146 (UMLS CUI [4,2])
C0935929 (UMLS CUI [5,1])
C1527415 (UMLS CUI [5,2])
C0332197 (UMLS CUI [5,3])
C0021641 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
Hemoglobin A1c measurement
Item
hba1c more than 7.5 and less than 11.
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose of >13.5mmol/l
boolean
C0583513 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes mellitus (t1dm)
boolean
C0011854 (UMLS CUI [1])
Illness | Hospitalization
Item
patient with acute illness hospitalized in last 2 months
boolean
C0221423 (UMLS CUI [1])
C0019993 (UMLS CUI [2])
C0019993 (UMLS CUI [2])
Liver disease | Renal Insufficiency | Liver Dysfunction
Item
patient with active liver disease, impaired renal or hepatic functions
boolean
C0023895 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
C0086565 (UMLS CUI [3])
C1565489 (UMLS CUI [2])
C0086565 (UMLS CUI [3])
Hypersensitivity Glimepiride | Sulfonylurea allergy | Allergy to sulfonamides | Hypersensitivity Amaryl Excipient
Item
known hypersensitivity to glimepiride, other sulfonylureas, other sulfonamides or any other excipients of amaryl
boolean
C0020517 (UMLS CUI [1,1])
C0061323 (UMLS CUI [1,2])
C0571636 (UMLS CUI [2])
C0038757 (UMLS CUI [3])
C0020517 (UMLS CUI [4,1])
C0595112 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0061323 (UMLS CUI [1,2])
C0571636 (UMLS CUI [2])
C0038757 (UMLS CUI [3])
C0020517 (UMLS CUI [4,1])
C0595112 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
pregnant and lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Considerations Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0518609 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])
C0518609 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])